Ready, Set, CROI 2023 – Prepare for the 30th Year of CROI
Re: Draft Recommendation Statement and Draft Evidence Review: Pre-Exposure Prophylaxis for the Prevention of HIV Infection
AVAC submits comment and response to the United States Preventative Services Task Force (USPSTF) Draft Recommendation statement for PrEP. The USPSTF recommended an “A” Grade for PrEP that includes CAB for PrEP.
HIV Vaccines: An introductory factsheet
This is an updated introductory two-page document that describes HIV vaccines research and reviews key developments in the field.
Biomedical HIV Prevention Research in 2022 and Beyond
This report provides a concise update on the full landscape of biomedical interventions: including PrEP products in the market and next-gen products in the pipeline—multipurpose products (MPTs), vaccines and broadly neutralizing antibodies.
Correlations between Oral Pre-Exposure Prophylaxis (PrEP) Initiations and Policies that Enable the Use of PrEP to Address HIV Globally
This article from PLoS Global Public Health presents the results of an analysis examining whether policies enabling broad PrEP eligibility, HIV self-testing, and lowered age of consent to HIV testing and treatment services are correlated with PrEP uptake.
Celebrating the Role of Communities: A focus on choice in HIV prevention
Presentation given by Rosemary Mburu, Executive Director of WACI Health, on World AIDS Day 2022 describing her organization and providing a short overview of the field.
Combination Prevention: Integrating strategies to end the epidemic
One-pager describing what “combination prevention” means.
Px Wire July-September 2022, Vol. 12, No. 2
PrEP Tracker data, preparing for new products, the HIV prevention pipeline and our prevention playlist. All that and more in the latest issue of Px Wire.
Cost of Goods Sold (COGS) Analyses
FAQ Debrief
This FAQ explains the use of Cost of Good Sold Analyses (COGS) and how they inform planning for product introduction.